

Published in final edited form as:

*J Mater Chem B Mater Biol Med.* 2015 January 7; 3(1): 119–126. doi:10.1039/C4TB01312C.

## Tri-peptide cationic lipids for gene delivery

Yinan Zhao<sup>a,b</sup>, Shubiao Zhang<sup>b,\*</sup>, Yuan Zhang<sup>c</sup>, Shaohui Cui<sup>b</sup>, Huiying Chen<sup>b</sup>, Defu Zhi<sup>b</sup>, Yuhong Zhen<sup>d</sup>, Shufen Zhang<sup>a,\*</sup>, and Leaf Huang<sup>e</sup>

<sup>a</sup>State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116021, Liaoning, China

<sup>b</sup>SEAC-ME Key Laboratory of Biotechnology and Bio-resources Utilization, Dalian Nationalities University, Dalian 116600, Liaoning, China

<sup>c</sup>Department of Materials Science and Engineering, Department of Biological Engineering, The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>d</sup>College of Pharmacy, Dalian Medical University, Dalian 116044, Liaoning, China

<sup>e</sup>Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

### Abstract

Several novel tri-peptide cationic lipids were designed and synthesized for delivering DNA and siRNA. They have tri-lysine and tri-ornithine as head groups, carbamate group as linker and 12 and 14 carbon atom alkyl groups as tails. These tri-peptide cationic lipids were prepared into cationic liposomes for the study of the physicochemical properties and gene delivery. Their particle size, Zeta potential and DNA-binding were characterized to show that they were suitable for gene transfection. The further results indicate that these lipids can transfer DNA and siRNA very efficiently into NCI-H460 and Hep-2 tumor cells. The selected lipid, CDO14, was able to deliver combined siRNAs against c-Myc and VEGF for silencing distinct oncogenic pathways in lung tumors of mice, with little *in vitro* and *in vivo* toxicity.

### 1 Introduction

Viral vectors and non-viral vectors are widely used to modulate gene expression in target tissues to correct genetic defects for gene therapeutic application. Viral vectors, such as adenovirus vectors, adeno-associated virus vectors, or retrovirus vectors, have been applied in clinical trials.<sup>1–3</sup> However, some side effects including immunoresponse and infection have been reported.<sup>4–5</sup> Non-viral gene delivery systems have, on one hand, been demonstrated as standard tools for *in vitro* transfection with many commercially available

© The Royal Society of Chemistry [year]

zhangshf@dlut.edu.cn; Tel: +86-411-84986265. zsb@dlu.edu.cn; Fax: +86-411-87656141; Tel: +86-411-87656141.

†Electronic Supplementary Information (ESI) available: IR, NMR, HR-ESI-MS and HPLC characterisation of all the lipids synthesized; TEM images of CDO14 liposome and CDO14 liposome/DNA lipoplex; Gel electrophoresis of liposome/pDNA complexes; *In vitro* transfection images against NCI-H460 and Hep-2 cells. See DOI: 10.1039/b000000x/

kits.<sup>6-8</sup> On the other hand, they are regarded as a promising approach for the treatment of genetic diseases and cancers.<sup>9-12</sup>

Among these non-viral vectors, peptide cationic lipids have drawn great attention,<sup>13-18</sup> as peptides are more biocompatible. Peptides and their derivatives have been used for restraining cancer cell migration, curing anti-thrombosis, treating acute renal failure, reducing anti-inflammation and promoting skin regeneration, etc. But the isolated small peptides are easily degraded by enzymes *in vivo*, and they could be cleared very quickly.<sup>19-20</sup> People found that the introduction of peptide groups into lipids can prolong their half-life *in vivo* and enhance targeting thereof.<sup>21</sup>

Therefore, peptides based cationic lipids have shown more superiorities over other cationic lipids, such as good biodegradability, excellent biocompatibility and targeting ability to cells, and potential application in improving the delivery of gene therapeutics.<sup>22-24</sup> However, the current peptides based cationic lipids still hold some limitations.<sup>25-26</sup> Therefore, we designed and synthesized a series of novel tri-peptide cationic lipids CDL12, CDL14, CDO12 and CDO14 (Fig. 1) for facilitating the use of peptides based lipids for gene delivery.

## 2 Experimental procedures

### Materials

9-Fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu), o-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), lauryl alcohol, myristyl alcohol, N,N'-carbonyldiimidazole (CDI), diethylenetriamine, 3-amino-1,2-propanediol, Lysine and Ornithine were purchased from Shanghai Aladdin Industrial Inc. (China). Lipofectamine 2000 was purchased from Invitrogen Life Technologies (USA). 1,2-Dioleoyl-3-trimethylammonium-propane chloride salt (DOPE) and anti-luciferase siRNA were purchased from Sigma-Aldrich (USA). 1,2-Dioleoyl-3-trimethylammoniumpropane (DOTAP) was purchased from Roche Shanghai (China). Hep-2 and NCI-H460 cells were purchased from the Institute of Biochemistry and Cell Biology (China). A549 cells were from Leaf's lab of the University of North Carolina at Chapel Hill. DMEM, RPMI1640, fetal bovine serum (FBS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Gibco (USA). Green fluorescent protein (pGFP-N2) and luciferase (pGL3) plasmid vectors were purchased from Sangon Biotech Co. Ltd. (China), and extracted in our lab. Bright-Glo™ Luciferase Assay System was purchased Promega Biotech Co. Ltd. (Beijing, China). All other chemicals were of reagent grade.

### Synthesis of lipids

The synthesis of these lipids was performed as follows, using CDL12 as an example (Scheme 1): CDI was added to lauryl alcohol in toluene and kept at reflux for 3 h. Diethylenetriamine was added. After another 3 h, the solvent was evaporated. The crude product was recrystallised from the mixture solvent of ethanol/water to give intermediate **1**. Boc<sub>2</sub>O in acetone was added to L-Lys aqueous solution. CuSO<sub>4</sub>·5H<sub>2</sub>O was added and kept stirring for 14 h at room temperature. Anhydrous sodium carbonate, 8-hydroxyquinoline and

Fmoc-OSu were added. The solution was stirred at room temperature for 6~7 h before being filtered. The filtrate was cooled to 0 °C, and pH was adjusted to 2~3 with HCl solution. The crude product was recrystallised from the mixture solvent of acetonitrile and petroleum ether to give intermediate **2** as Fmoc-Lys (Boc)-OH.

For the construction of CDL12, intermediate **2** was added to HATU in dichloromethane. After reaction of 1 h, dichloromethane solution of intermediate **1** was added. Boc group was removed with CHCl<sub>3</sub>/TFA (1:1) and Fmoc group with dioxane/NaHCO<sub>3</sub> to give intermediate **3** as H-Lys-OCD12. The reaction was repeated as the above steps to give the crude product with intermediates **2** and **3**. The resulting sticky paste was recrystallised from the mixed solvent of acetonitrile and petroleum ether to give white crystal as CDL12.

### Chemical analysis of lipids

<sup>1</sup>H and <sup>13</sup>C NMR spectra were measured at 400 and 100 MHz, respectively, on a Varian Mercury Plus 400 spectrometer. High resolution electrospray ionization mass spectrometry was performed using a Q-ToF Micro (Micromass Inc., Manchester, UK). IR spectra were recorded using an IRPrestige-21 (Shimadzu, JAPAN). HPLC was performed on a LC-20AB (Shimadzu, JAPAN) with a C18 column, 1% TFA in methanol/water mobile phase (85:15), the flow rate of 0.8 mL/min.

### Preparation and characterisation of liposomes

The protocol for preparation of liposomes based on CDL12, CDL14, CDO12 and CDO14 lipids was optimised to obtain high-quality delivery systems. The lipids were formulated in combination with the neutral lipid DOPE in 1:1 molar ratio. To prepare liposomes, a suitable amount of lipid and DOPE were dissolved in 1 mL of chloroform in a 5 mL glass vial. The solvent was removed under a stream of nitrogen gas, followed by high-vacuum desiccation. The dry lipid film was resuspended in 1 mL distilled water to give liposomes in a concentration of approximately 1 mg/mL. The liposome/DNA complexes of varying weight ratios (N/P) were prepared by mixing liposomes with plasmid solutions 20 min before use.

### Particle size and Zeta potential measurements

The particle size and Zeta potential were measured with a Malvern ZetaSizer Nano series (Westborough, MA) at room temperature. All the lipoplexes of varying N/P ratios ranging from 1 to 8 were prepared with pGL3 plasmid. For the measurement of particle size and Zeta potential, 20 µL of the liposomes or lipoplexes were diluted to 1 mL with distilled water.

### Agarose gel retardation assay

The lipoplexes of varying N/P ratios ranging from 0 to 8 were prepared with pGL3 plasmid. The lipoplexes were electrophoresed in 1.2 % agarose gel containing GelRed and Tris-acetate (TAE) running buffer at 90 V for 40 min. DNA bands were visualised in a gel documentation unit (Syngene, Britain).

### ***In vitro* pDNA transfection**

Hep-2 and NCI-H460 cells were seeded in 24-well plates ( $5.0 \times 10^4$  cells/well), and incubated at 37 °C under 5 % CO<sub>2</sub> until approximately 80 % confluence was attained. The medium was removed and replaced with 100 µL serum-free DMEM per well. Cationic liposome/DNA lipoplexes were then added to the plates and incubated for 4 h at 37 °C. The medium was then replaced with DMEM containing 10 % FBS and 1 % antibiotics, and the cultures were maintained at 37 °C under 5 % CO<sub>2</sub> for 48 h.

The expression of green fluorescent protein was measured using an inverted fluorescence microscope (Olympus IX71, Japan). Relative luciferase activity was assessed using a Bright-Glo™ Luciferase Assay System and Synergy™ 2 Multi-Detection Microplate Reader. Briefly, the growth medium was removed from each well, and luciferase activity was measured after lysis buffer was added. The total protein concentration in the cell lysate was measured using a BCA protein assay kit and luciferase activity was expressed as relative light units (RLU) per mg protein.

### ***In vitro* siRNA transfection**

A549 cells expressing firefly luciferase were seeded in 12-well plates ( $1.0 \times 10^5$  per well) approximately 24 h before experiments. Cells were treated with different lipid formulations at the anti-luciferase siRNA concentration of 40 nM in Opti-MEM at 37 °C for 4 h. Cells were washed with DPBS, followed by incubation with lysis buffer at room temperature for 20 min.

Fluorescence intensity in cell lysate was determined using a Perkin-Elmer LS 50B luminescence spectrometer (Norwalk, CT) ( $\lambda_{ex}$ , 494 nm;  $\lambda_{em}$ , 519 nm). Cell lysate (5 µg per well) was dissolved in BCA protein assay reagent, and total protein concentrations determined at 570 nm. The silencing rate is expressed as relative light units (RLU) per microgram of total protein.

### **Cytotoxicity of the cationic liposomes**

The assay was performed in 96-well plates by maintaining the N/P weight ratios as used in the transfection experiments. The cells were seeded in 96-well plates and incubated at 37 °C under 5 % CO<sub>2</sub> for 24 h to get a confluence of about 80 %. After the replacement of medium, the liposomes/DNA complexes were added to the cells for further culture at 37 °C under 5 % CO<sub>2</sub> for 24 h, and then MTT (20 µL, 5 mg/mL) was added and kept for 4.5 h. The absorbance at 570 nm was monitored by using the enzyme mark instrument (Sunrise Tecan, Australia).

### **Animals**

*In vivo* studies were carried out on BALB/c nude mice of age 4–6 weeks. All experiments performed on the animals were in accordance with and approved by the Institutional Animal Care and Use Committee at University of North Carolina.

### ***In vivo* gene silencing study**

Combined siRNAs against c-Myc and VEGF (1:1) were co-delivered by CDO14 liposome. The tumor-bearing mice were injected IV times every 3 days via tail vein with lipoplexes at the N/P ratio of 3:1 (with a dose of 0.45 mg total siRNA/kg). One day after the third injection, the mice were killed and the tumor-loaded lungs were collected for the preparation of paraffin embedded sections (4-5  $\mu$ m thick). Expressions of c-Myc and VEGF in the sections were examined immunohistochemically using the antibodies from a kit in accordance with the product protocol.

### **TUNEL assay**

TUNEL staining was performed as recommended by the manufacturer's protocol (Promega, Madison, WI). Tumor-bearing mice were given i.v. injections of the siRNA formulated in the CDO14 on days 9 and 10. Twenty-four hours after the second injection, the mice were killed, and the tumor-loaded lungs were collected for the TUNEL staining. The nuclei were counterstained with hematoxylin, and the samples were imaged using an inverted fluorescence microscope (Olympus IX71, Japan).

### **Toxicity of the cationic liposomes *in vivo***

The tumor-bearing mice were i.v. injected with siRNA formulated in the targeted liposome at 3:1 doses, and the serum cytokine level was determined with Olympus AU400 Automatic Biochemistry Analyzer. Mouse body weight was also monitored.

### **Statistical analysis**

The data were presented as mean values  $\pm$  SD. The statistical significance was determined using two-way analysis of variance. *P* values <0.05 were considered significant.

## **3 Results and discussion**

### **Design and synthesis of cationic lipids**

The tri-peptide cationic lipids designed are composed of three biocompatible molecular moieties: tri-lysine peptides or tri-ornithine peptides (the cationic headgroup), carbamate (the linker), and two hydrocarbon chains (hydrophobic tails). These tri-peptide cationic lipids were prepared by adapting a straight forward procedure (Scheme 1). Intermediate **1** was obtained from carbonyldiimidazole, dodecyl alcohol and triethylenetetra-amine. The synthesis of intermediate **2** started with Fmoc and Boc groups protected lysine. After the condensation under HATU activation and the deprotection by using TFA and NaHCO<sub>3</sub>, intermediate **3** could be given. Following the same procedure by using another 2 mol Boc and Fmoc protected lysine; we got tri-peptide cationic lipids for further chemical analysis and biological study.

The structures and purities of tri-peptide cationic lipids were characterised by electrospray ionisation-mass spectrometry (ESI-MS), proton nuclear magnetic resonance spectroscopy (<sup>1</sup>H NMR, <sup>13</sup>C NMR), infrared (IR) spectroscopy, and high pressure liquid chromatography (HPLC) (Fig. S1–S4, ESI<sup>†</sup>). The analytical data of these compounds are listed under the figures in the ESI<sup>†</sup> to show that tri-peptide cationic lipids were successfully obtained.

### Particle size, and Zeta-potential of tri-peptide cationic liposomes and lipoplexes

Our previous study showed that liposomes had higher transfection efficiency with equivalent molar ratio of DOPE, so the liposomes were prepared by using the tri-peptides with DOPE as co-lipid at a molar ratio of 1:1. The dynamic light scattering showed the particle sizes of these liposomes were from 70 nm to 150 nm, those for the lipoplexes of CDO14/DNA were from 200 nm to 400 nm in the N/P ratio range from 1:1 to 8:1 (Fig. 2, 3). Zeta potentials of liposomes were between 40–60 mV, which ensured the stability of the liposomes for at least three months. Zeta potentials of the lipoplexes of CDO14/DNA were found to increase from –50 mV to nearly 0 mV with the increase of the N/P ratios from 1:1 to 8:1 (Fig. 2, 3). The sizes and Zeta potentials were in the ranges suitable for gene transfection.<sup>27</sup> The morphological characteristics were directly visualised by transmission electron microscopy (TEM) (Fig. S5, ESI<sup>†</sup>). Images obtained from CDO14 liposome and CDO14 liposome/DNA lipoplex at the N/P ratio of 3:1 revealed well-defined spherical structures.

### DNA-binding assay

DNA-binding with liposomes is a key factor for gene transfection.<sup>28</sup> Therefore, the electrostatic binding interactions between plasmid DNA and the tri-peptide cationic liposomes were measured by the gel retardation assay across the N/P ratios of 0:1–8:1. Findings in the gel retardation assay revealed all the liposomes could start to retard the plasmid DNA at the N/P ratio of 0.5:1. They could nearly completely retard pDNA at higher N/P ratios of 6:1, 6:1, 6:1 and 3:1 for CDL12, CDL14, CDO12 and CDO14, respectively. Though all the above liposomes could bind pDNA at higher N/P ratios, the lower N/P ratio of CDO14 for retardation compared with other liposomes may reduce its dose required to obtain maximal transfection efficiency. The above results demonstrate that cationic liposomes can form DNA-liposomes complexes at different N/P ratios. This ensured the entry of pDNA into cells and the protection of pDNA from degradation by DNase. (Fig. S6, ESI<sup>†</sup>).

### *In vitro* pDNA and siRNA transfection

The *in vitro* transfection of these liposomes was evaluated using pGFP-N2 plasmid DNA and pGL3 plasmid DNA against Hep-2 and NCI-H460 cells. The expression of pGFP-N2 and pGL3 is illustrated in Fig. 4 (more details to see Fig. S7 and Fig. S8, ESI<sup>†</sup>) and Fig. 5, respectively. The results indicate that all the lipids were comparable to Lipofectamine 2000 and DOTAP in terms of GFP and luciferase expression. They had higher transfection against Hep-2 cells than against NCI-H460 cells. The liposomes with ornithine headgroup also showed higher transfection than those with lysine headgroup, perhaps because they have smaller heads.

Through the above experiments, the transfection in cells will undergo the following process. First, the plasmid DNA binds to the tri-peptide head-groups of the cationic lipids. Then, the lipids/DNA lipoplexes will enter the Hep-2 cells and NCI-H460 cells (e.g., via endocytosis), and trypsin in the cell will hydrolyze the carbamate bond in the lipids. The hydrolyzation assists DNA to escape from the endosome for the subsequent transcription. The whole process is readily performed and thus enhances DNA transfection efficiency.

Tri-peptide lipids were screened for the ability to deliver siRNA to A549 lung carcinoma cells which can stably express firefly luciferase (Fig. 6). The efficacy of siRNA delivery by these tri-peptide lipids was determined by treating cells with siRNA-complexes, prepared using a firefly luciferase targeting siRNA (siLuc).<sup>29-30</sup> Overall, all four lipids showed gene silencing compared with the control. Three of them were better than DOTAP, and CDO14 and CDL14 were slightly better than Lipofectamine 2000, silencing nearly 75 % of luciferase in A549 cells. Much work has been carried out on modifying cationic lipids for use in gene transfection, to determine if there is a 'best' chain length.<sup>31</sup> However, solid conclusions are rarely obtained, for the conclusions of these studies are frequently contradictory. In this study, CDL14 and CDO14 showed superior siRNA delivery. It may maintain an appropriate balance between fluidity and rigidity for entering into cells, and have the ability to release siRNA in cells due to the carbamate linker.

### Cytotoxicity of the cationic liposomes

Cytotoxicity of gene delivery materials could be measured by the MTT method. Cell viabilities after exposure to lipids, CDL12, CDL14, CDO12 and CDO14, were evaluated in NCI-H460 cells and Hep-2 cells across the entire range of N/P weight ratios used in the transfection experiments. Cells could tolerate all the lipids at relatively low N/P ratios (under 4:1), better than the commercial liposomes, Lipofectamine 2000 and DOTAP (Fig. 7). The lower cytotoxicity of these lipids should be contributed to the nature of the peptide headgroups, as they are more biocompatible over quaternary ammonium with cells, thus increasing the toleration of cells to them.<sup>19, 24</sup>

### *In vivo* gene silencing study

Since cationic lipid CDO14 showed optimal *in vitro* pDNA and siRNA transfection, its *in vivo* delivery was studied. Combined siRNAs against c-Myc and VEGF (1:1) were delivered by CDO14 liposome. The A549 lung tumor bearing mice were injected 3 times every 3 days via tail vein with lipoplexes at the N/P ratio of 3:1 (with a dose of 0.45 mg total siRNA/kg). As immunohistochemistry could give clear conclusion of RNA interference,<sup>17, 31-32</sup> the gene silencing activity was measured by using this method. As shown in Fig. 8, the protein expression of c-Myc and VEGF in the lung tumor was suppressed by the combined siRNAs delivered with CDO14 liposome. The results indicate that the combined siRNAs formulated in CDO14 liposome were able to simultaneously silence the expressions of the target oncogenes in the lung tumors. The successful interference of combined siRNAs to different genes opens a door by silencing multi-oncogenic pathways by using tri-peptide cationic lipids. This increases the possibility of CDO14 as a potential candidate for the further *in vivo* study and clinical trials.

### TUNEL assay

Apoptotic induction plays an essential role in the suppression of tumor cell proliferation.<sup>33</sup> We examined the apoptosis induced by siRNAs using the TdT dUTP nick end-labeling (TUNEL) staining (Fig. 9). As shown in the figure, the number of TUNEL-positive cells increased after intravenous injections of siRNA formulated in CDO14 liposome. Intravenous injections of siRNA in the control group showed only a slight increase in TUNEL-positive

cells. No significant apoptotic induction was observed in other treatment groups. These results suggest that this formulation triggered cell death and might play a critical role in regulating the survival of A549 lung cancer cells *in vivo*.

### Toxicity of the cationic liposomes *in vivo*

In addition to therapeutic effect, toxicity is a crucial parameter of a therapeutic agent for clinical use. At the therapeutic dose (0.45 mg/kg), the formulation did not induce significant elevation of renal indicators and liver enzymes, including blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Table 1). Additionally, the body weights of mice were stably increased after post injection of lipoplexes at the therapeutic dose (Fig. 10). The results indicate the formulation containing CDO14 did not induce obvious toxicity to mice. The toxicity to cells and animals is a major obstacle for the clinical trials of cationic lipids, as the cationic lipids with quaternary ammonium headgroup can become cytotoxic by interacting with critical enzymes such as PKC.<sup>34</sup> Therefore, the toxicity of cationic lipids is mainly determined by their cationic nature. The replacement of quaternary ammonium with tri-peptide increased the affinity and biocompatibility, thereby, increasing their transfection and lowering toxicity.

## 4 Conclusion

In summary, we selected the tri-peptide Lys-Lys-Lys and Orn-Orn-Orn as the headgroups for the gene delivery study, because both lysine and ornithine are found in a number of structurally characterized DNA binding domains of proteins. These cationic lipids are relatively simple to synthesize by using standard peptide chemistry, and their chemical structures can readily be tailored for effective interaction with DNA. The *in vitro* delivery results of pDNA and siRNA by these tri-peptide lipids against NCI-H460 and Hep-2 tumor cells show that they could lead to superior transfection compared to conventional non-viral transfection reagents. They also showed lower cytotoxicity against the two tumor cells. The lipid CDO14 with ornithine as headgroup and 14 carbon atom alkyl groups at tails demonstrated better transfection over other lipids. It was selected to be used for *in vivo* evaluation. It showed not only enhanced transfection activity, but also very low toxicity *in vivo*. CDO14 could be able to deliver combined siRNAs against c-Myc and VEGF for silencing distinct oncogenic pathways in lung tumors of mice. The results of this study strengthen the validity of the peptides based cationic lipids as a drug delivery vehicle for cancer therapy.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements


This research is financially supported by the National High Technology Research and Development Program (863 Program) of China (2014AA020707), the National Natural Science Foundation of China (20876027 and 21176046), the Fundamental Research Funds for the Central Universities (DC12010104) and NIH grants (CA129835, CA129421, CA149363).




## Notes and references

1. Crystal RG. *Science*. 1995; 270:148–151.
2. Chandrashekhar V, Srujan M, Prabhakar R, Reddy RC, Sreedhar B, Rentam KKR, Kanjilal S, Chaudhuri A. *Bioconjugate Chem*. 2011; 3:497–509.
3. Xiu KM, Zhao NN, Yang WT, Xu F. *Acta Biomater*. 2013; 9:7439–7448. [PubMed: 23571001]
4. Donahue RE, Kessler SW, Bodine D. *J. Exp. Med*. 1992; 176:1125–1135. [PubMed: 1383375]
5. Sun JY, Anand-Jawa V, Chatterjee S. *Gene Ther*. 2003; 10:964–976. [PubMed: 12756417]
6. Nakagawa O, Ming X, Huang L, Juliano RL. *J. Am. Chem. Soc*. 2010; 132:8848–8849. [PubMed: 20550198]
7. Zhi DF, Zhang SB, Qureshi F, Zhao YN, Cui SH, Wang B, Chen HY, Yang BL, Zhao DF. *Colloid. Surface B*. 2013; 1:537–541.
8. Bishop CJ, Ketola T-M, Tzeng SY, Sunshine JC, Urtti A, Lemmetyinen H, Vuorimaa-Laukkanen E, Yliperttula M, Green JJ. *J. Am. Chem. Soc*. 2013; 18:6951–6957. [PubMed: 23570657]
9. Altieri S, Balzi M, Bortolussi S, Bruschi P, Ciani L, Clerici AM, Faraoni P, Ferrari C, Gadan MA, Panza L, Pietrangeli D, Ricciardi G, Ristori S. *J. Med. Chem*. 2009; 52:7829–7835. [PubMed: 19954249]
10. Zhang SB, Zhao YN, Zhao BD, Wang B. *Bioconjugate Chem*. 2010; 21:1003–1009.
11. Zhi DF, Zhang SB, Cui SH, Zhao YN, Wang YH, Zhao DF. *Bioconjugate Chem*. 2013; 24:487–519.
12. Zhang SB, Zhao YN, Zhi DF, Zhang SF. *Bioorganic Chem*. 2012; 40:10–18.
13. Rea JC, Gibly RF, Barron AE. *Acta Biomater*. 2009; 5:903–912. [PubMed: 18990615]
14. Coles DJ, Esposito A, Chuah HT. *Tetrahedron*. 2010; 66:5435–5441.
15. Zhou D, Li C, Hu YL, Zhou H, Chen JT, Zhang ZP, Guo TY. *Chem. Commun*. 2012; 48:4594–4596.
16. Jiang M, Gan L, Zhu CL, Dong Y, Liu JP, Gan Y. *Biomaterials*. 2012; 30:7621–7630. [PubMed: 22789720]
17. Gehin C, Montenegro J, Bang E-K, Cajaraville A, Takayama S, Hirose H, Futaki S, Matile S, Riezman H. *J. Am. Chem. Soc*. 2013; 135:9295–9298. [PubMed: 23767803]
18. Saha A, Mondal G, Biswas A, Chakraborty I, Jana B, Ghosh S. *Chem. Commun*. 2013; 49:6119–6122.
19. Zhao YN, Zhang SB, Cui SH, Wang B, Zhang SF. *Expert Opin. Drug Del*. 2012; 1:127–139.
20. Wang KW, Yan XH, Cui Y, He Q, Li JB. *Bioconjugate Chem*. 2007; 18:1735–1738.
21. Weiss A, Neuberg P, Philippot S, Erbacher P, Weill CO. *Biotechnol. Bioeng*. 2011; 108:2477–2487. [PubMed: 21520021]
22. Ashley CE, Carnes EC, Epler KE, Padilla DP, Phillips GK, Castillo RE, Wilkinson DC, Wilkinson BS, Burgard CA, Kalinich RM, Townson JL, Chackerian B, Willman CL, Peabody DS, Wharton W, Jeffrey Brinker C. *ACS NANO*. 2012; 3:2174–2188. [PubMed: 22309035]
23. Rajesh M, Sen J, Srujan M, Mukherjee K, Sreedhar B, Chaudhuri A. *J. Am. Chem. Soc*. 2007; 129:11408–11420. [PubMed: 17718562]
24. Lamanna CM, Lusic H, Camplo M, McIntosh TJ, Barthelemy P, Grinstaff MW. *Accounts Chem. Res*. 2012; 7:1026–1038.
25. Takeuchi T, Montenegro J, Hennig and Matile, S A. *Chem. Sci*. 2011; 2:303–307.
26. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. *Nature*. 2010; 464:1067–1070. [PubMed: 20305636]
27. Sarker SR, Aoshima Y, Hokama R, Inoue T, Sou K, Takeoka S. *Int. J. Nanomed*. 2013; 8:1361–1375.
28. Obata Y, Saito S, Takeda N, Takeoka S. *BBA-Biomembranes*. 2009; 1788:1148–1158. [PubMed: 19249283]
29. Qu W, Qin SY, Kuang Y, Zhuo RX, Zhang XZ. *J. Mater. Chem. B*. 2013; 1:2147–2154.
30. Zeng HX, Little HC, Tiambeng TN, Williams GA, Guan ZB. *J. Am. Chem. Soc*. 2013; 135:4962–4965. [PubMed: 23496091]


31. Willibald J, Harder J, Sparrer K, Conzelmann KK, Carell T. *J. Am. Chem. Soc.* 2012; 134:12330–12333. [PubMed: 22812910]
32. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H, Baba Y, Harashima H. *Biomaterials.* 2011; 32:4306–4316. [PubMed: 21429576]
33. Li H, Zhu H, Xu CJ. *Cell.* 2008; 94:491–501. [PubMed: 9727492]
34. Lv HT, Zhang SB, Wang B, Cui SH, Yan J. *J. Control. Release.* 2006; 114:100–109. [PubMed: 16831482]




**Fig. 1.**  
Structures of tri-peptide cationic lipids CDL12, CDL14, CDO12 and CDO14.



**Fig. 2.** Particle size and Zeta potential of tri-peptide liposomes. Liposomes (20  $\mu$ L) were diluted in 1 mL distilled water. Particle size (A) and Zeta potential (B) were measured using a Malvern ZetaSizer. The PDI of CDL12, CDL14, CDO12, CDO14, Lipofectamine 2000 and DOTAP was 0.286, 0.262, 0.296, 0.422, 0.306 and 0.242, respectively.




**Fig. 3.** Particle size and Zeta potential of tri-peptide lipoplexes. Particle size (A) and Zeta potential (B) were measured using a Malvern ZetaSizer. The PDI of lipoplexes from left to right was 0.427, 0.292, 0.391, 0.192, 0.296, 0.210, 0.206 and 0.189, respectively.




**Fig. 4.**

Fluorescent images (20×10) of GFP gene expression in NCI-H460 and Hep-2 cells using tripeptide liposomes at the N/P ratio of 3:1 (the amount of pGFP-N2 was 0.5  $\mu$ g/well, 96-well plates). As controls, Lipofectamine 2000 and DOTAP were used at the N/P ratio of 3:1. (A: NCI-H460, B: Hep-2; 1–6 were CDL12, CDL14, CDO12, CDO14, Lipofectamine 2000 and DOTAP, respectively.)




**Fig. 5.** Luciferase expression in tumor cells using tri-peptide liposomes at N/P ratios from 1:1 to 8:1 (the amount of pGL3 was 0.5  $\mu$ g/well, 96-well plates). As controls, DOTAP and Lipofectamine 2000 were used at an N/P ratio of 3:1, as suggested by the protocols. (A) NCI-H460, (B) Hep-2. Statistical analysis was accomplished by a two-way ANOVA: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .




**Fig. 6.** Gene silencing in A549 cells was determined by luciferase assay after 48 h. A549 cells were treated with firefly luciferase targeting siRNA-peptide lipid complexes at the N/P ratio of 3:1 (the amount of pGL3 was 0.5  $\mu$ g/well, 96-well plates). Statistical analysis was accomplished by a two-way ANOVA: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .







**Fig. 7.** Cytotoxicity of the tri-peptide lipids against NCI-H460 and Hep-2 cells, 48 h after the addition of lipoplexes formulated from liposomes and GFP plasmids. The cell viability of negative control cells was designated as 100 %. The positive controls were Lipofectamine 2000 and DOTAP, which were formulated with GFP plasmids to form lipoplexes at a ratio of 3:1 (A: NCI-H460, B: Hep-2).




**Fig. 8.** Immunohistochemical analysis of the lung tumor. SiRNAs against c-Myc and VEGF were delivered with (left) or without (right) CDO14 liposome.



**Fig. 9.** TUNEL staining of A549 lung tumors on day 9 after 3 consecutive i.v. injections on day 0, 3, 6 of combined siRNAs.



**Fig. 10.**  
The weight changes of mice after injections of lipoplex.

**Scheme 1.**

Synthesis of tri-peptide lipid CDL12. Reaction conditions: (A)  $\text{CH}_2\text{Cl}_2$ , 40 °C, 3 h; (B) THF, 40 °C, 3 h; (C)  $\text{H}_2\text{O}$ , 27 °C, 30 h; (D) room temperature, 4 h; (E), (H), (I)  $\text{CH}_2\text{Cl}_2$ , 20 °C, 12 h; (F), (J)  $\text{CHCl}_3$ , 4 °C, 2 h; (G), (K) Dioxane, room temperature, 2 h.

Reagents:  $(\text{Boc})_2\text{O}$  = Di-tert-butyl dicarbonate, Fmoc-OSu = 9-Fluorenylme-thyl-succinimidyl-carbonate, HATU = Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, TFA = Trifluoroacetic acid.

**Table 1**

Toxicity of lipoplex containing CDO14 to kidney and liver.

	Kidney		Liver	
	BUN mg/dL	Creatinine mg/dL	AST U/L	ALT U/L
CDO14 Lipoplex	18	0.1	87	51
	20	0.2	102	59
	24	0.2	82	59
Control	20	0.1	112	97
	19	0.1	157	71
Normal	8–33	0.1–0.2	54–298	17–77